Skip to main content
Staff Login
Username
*
Enter your The Contraceptive Pipeline Database username.
Password
*
Enter the password that accompanies your username.
Log in
Forgot password
Toggle navigation
Vicriviroc + MK2048 + Progestin Vaginal Ring
Product Overview
Development Status:
Active Development
Target:
Female
Mode:
Hormonal
Delivery Type:
Vaginal Ring
Duration Type:
Long-acting
Description:
A vaginal ring whose mechanism of action is CCR5 inhibitor, integrase inhibitor and a progestin for protection against HIV and pregnancy.
Updated date:
May 11, 2015
Vertical Tabs
Product Details
Active Pharmaceutical Ingredient (API):
MK2048
,
progestin
,
Vicriviroc
Inactive material:
EVA
Potential Multi-Purpose Technology (MPT):
Yes
Partner:
DAIDS
,
Merck
,
NIAID
Status
Project Phase:
Early Development
Project Stage:
Pre-clinical
Status Details:
2-ARV IVR prototype first in human study planned in early 2015. 2-ARV+progestin IVR prototype in preclinical development.
Merck announced that it would discontinue development of its investigational CCR5 antagonist vicriviroc for the treatment of HIV infection in both treatment-naive and treatment-experienced patients, due to unimpressive results in clinical trials.
Programmatic Considerations
Considerations:
Nuvaring technology licensed, manufacturing infrastructure. Nuvaring postmarket acceptability studies completed.
Additional Information
Footnotes:
Vicriviroc is also known as MK4176.
Download Product Report
